FDA in India may do surprise inspections; GSK sees bulk sales fall in India on protest; Aesica expands aseptic capacity;

@EricPFierce: Projecting $140M annual operating losses, Boehringer says Ben Venue plant not worth keeping open. Story | Follow @EricPFierce

> The FDA's India office is reportedly considering doing surprise inspections there. Story

> GlaxoSmithKline ($GSK) reported that bulk sales of drugs in India have fallen off, reportedly after some buyers stopped orders in protest over new government pricing policies. Report

> The FDA has let doctors know that there will be a shortage of Janssen's ovarian cancer drug Doxil but that Sun Pharma Global has enough of its generic to supply the U.S. market. Release

> U.K.-based CDMO Aesica has extended its aseptic capabilities at its Nottingham site to produce drugs in pre-filled syringes for clinical trials in the U.S. and Europe and small commercial production for the U.K. Release

> The European Medicines Agency said that for the first time it and regulators in Japan will share some good manufacturing practice (GMP) data to reduce the numbers of plant inspections for some drugmakers. Release

> Hospira ($HSP) is voluntarily recalling one lot of 1% Lidocaine HCl Injection after stainless steel particles were found in a vial. Release

> Drugmakers are seeking clarity around draft guidance about what actions tied to plant inspections might lead to the FDA banning their products from import into the U.S. Report

And Finally... Ohio is reportedly looking to compounding pharmacies to make execution drugs it has been unable to acquire from manufacturers. Story